Chester County News and Community Website
DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) this week announced that the results from the Phase 3 CONNECT-FX study of Zygel for the treatment of behavioral symptoms in children …
Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel Read More
CHESTERBROOK, PA — Trevena, Inc. (Nasdaq: TRVN) recently reported positive clinical data for TRV045, its selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator. The 3-part randomized, double-blind, placebo-controlled Phase 1 study …
Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator Read More
MALVERN, PA — TELA Bio, Inc. (NASDAQ: TELA) recently announced the publication of the 24-month analysis from the BRAVO Study in Annals of Medicine and Surgery.
TELA Bio, Inc. Announces Study Results Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) recently announced new data published in the peer-reviewed Journal of Endourology demonstrate the minimally invasive Prostatic Urethral Lift (PUL) procedure using the UroLift® System …
New Data: PUL with UroLift System Leads to Consistent BPH Outcomes Read More DEVON, PA — Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE) presented a poster at the recent 2022 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit in Washington, …
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome Read More
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of Phase 2a clinical study data in The Journal of Prevention of Alzheimer’s Disease.
Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer’s Disease Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced that the Independent Data and Safety Monitoring Board (DSMB) for the OCU400 Phase 1/2 clinical trial recently completed a review of safety …
Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2 Read More
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the U.S. Food and Drug Administration (FDA) recently authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer’s Disease …
Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer’s Disease Read More
In an effort to ensure the safety and well-being of children involved in clinical trials, the U.S. Food and Drug Administration (FDA) recently issued draft guidance that provides the agency’s …
FDA Issues Draft Guidance on Including and Protecting Children in Clinical Trials Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced the publication of “A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects” which appeared in Frontiers in Immunology. BBV152, commercialized …
Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology Read More